Drugs / HB0034
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06716151 | Dec 2024 → Nov 2025 overdue | — | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05512598 | Nov 2022 → Nov 2023 | generalized pustular psoriasis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06477536 | Sep 2024 → Dec 2025 overdue | generalized pustular psoriasis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05460455 Comparator | Oct 2022 → Jun 2023 | — | Shanghai Huaota Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05064345 Comparator | Dec 2021 → Sep 2022 | — | Shanghai Huaota Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06231381 Comparator | Feb 2024 → Feb 2025 overdue | generalized pustular psoriasis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0034 | “This is a multi-dose escalation study of HB0034 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034.” NCT05460455 ↗ |
| Action | Inhibit | “Anti-IL-36R” NCT05064345 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-IL-36R Monoclonal antibody” NCT05064345 ↗ |
| Route | Intravenous | “single intravenous infusion of HB0034” NCT06231381 ↗ |